Lymph Node Dissection in Curative Gastrectomy for Advanced Gastric Cancer

Table 5

Randomized controlled trials comparing D2 with D2 plus para-aortic lymph nodes.

Study	Country	Comparison	Postoperative; morbidity	Postoperative; mortality	5-year survival
JCOG trial; (1995–2001)	Japan	D2 (𝑛=263); D2+ PALN (𝑛=260)	20.9%; 28.1%; (𝑃=.067)	0.8%; 0.8%; (𝑃=.99)	69.2%; 70.3%; HR 1.03; (95% CI, 0.77–1.37)
Polish trial; (1999–2003)	Poland	D2 (𝑛=141); D2+ PALN (𝑛=134)	27.7%; 21.6%; (𝑃=.248)	4.9%; 2.2%; (𝑃=.37)	Under analysis
East Asian trial; (1995–2002)	Japan, Korea, and Chinese Taiwan area	D2 (𝑛=135); D2+ PALN (𝑛=134)	26%; 39%; (𝑃=.023)	0.7%; 3.7%; (𝑃=.107)	52.6%; 55.4%; (𝑃=.801)

D2: gastrectomy with D2 lymph node dissection. PALN: para-aortic lymph node dissection.